Ethnicity based differences in statin use and hypercholesterolemia control among patients with premature coronary artery disease-results of I-PAD study

[1]  Ewout W. Steyerberg,et al.  Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease , 2020, BMC Medical Informatics and Decision Making.

[2]  N. Mohammadifard,et al.  Rationale, design, and preliminary results of the Iran-premature coronary artery disease study (I-PAD): A multi-center case-control study of different Iranian ethnicities , 2020, ARYA atherosclerosis.

[3]  L. Tokgözoğlu,et al.  [Evaluation of statin use on LDL cholesterol levels in Turkey: A systematic review]. , 2020, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[4]  K. Fox,et al.  Treatment Patterns, Statin Intolerance, and Subsequent Cardiovascular Events Among Japanese Patients With High Cardiovascular Risk Initiating Statin Therapy. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[5]  H. Daida,et al.  Racial Differences in the Cholesterol-Lowering Effect of Statin , 2017, Journal of atherosclerosis and thrombosis.

[6]  P. Thompson,et al.  Statin-Associated Side Effects. , 2016, Journal of the American College of Cardiology.

[7]  Andrew E Moran,et al.  Demographic and epidemiologic drivers of global cardiovascular mortality. , 2015, The New England journal of medicine.

[8]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[9]  D. Mahmood,et al.  Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective , 2014, Journal of the Saudi Heart Association.

[10]  A. Mirzazadeh,et al.  Hypertension: diagnosis, control status and its predictors in general population aged between 15 and 75 years: a community-based study in southeastern Iran , 2014, International Journal of Public Health.

[11]  Y. Sugiyama,et al.  Ethnic Variability in the Plasma Exposures of OATP1B1 Substrates Such as HMG‐CoA Reductase Inhibitors: A Kinetic Consideration of Its Mechanism , 2013, Clinical pharmacology and therapeutics.

[12]  B. Norrving,et al.  Global atlas on cardiovascular disease prevention and control. , 2011 .

[13]  M. Ohtawa,et al.  Sex difference in metabolism of simvastatin by rat hepatic microsomes , 1992, European Journal of Drug Metabolism and Pharmacokinetics.

[14]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[15]  R. Collins,et al.  SLCO1B1 variants and statin-induced myopathy--a genomewide study. , 2008, The New England journal of medicine.

[16]  Paul D. Martin,et al.  Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia , 2008 .

[17]  Cholesterol Treatment Trialists' Collaborators.  Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.

[18]  Yusong Chen,et al.  Increased systemic exposure to rosuvastatin in Asian subjects residing in the United States compared with Caucasian subjects , 2008 .

[19]  T. Tzeng,et al.  Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia. , 2008, Current medical research and opinion.

[20]  S. Higuchi,et al.  Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy , 2006, Expert opinion on drug metabolism & toxicology.

[21]  Yasuo Ohashi,et al.  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.

[22]  T. C. Smale.  NEW INHIBITORS OF CHOLESTEROGENESIS PRODUCED BY PENICILLIUM CITRINUM , 2006 .

[23]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[24]  A. Marian,et al.  Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.

[25]  M. Kuroda,et al.  Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme a reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity , 1976, Atherosclerosis. Supplements.

[26]  I. Vermes,et al.  Genetic Polymorphisms in Cytochrome P450 Enzymes , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[27]  M. Ryska,et al.  Differences Between Lovastatin and Simvastatin Hydrolysis in Healthy Male and Female Volunteers: Gut Hydrolysis of Lovastatin is Twice that of Simvastatin , 2003, TheScientificWorldJournal.

[28]  Peter Neuhaus,et al.  Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.

[29]  V. Zammit,et al.  Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities. , 2002, Diabetes.

[30]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .

[31]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[32]  D Kromhout,et al.  Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. , 1995, JAMA.

[33]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[34]  M. Noakes,et al.  Gender and diet interactions with simvastatin treatment. , 1994, Atherosclerosis.

[35]  M. Ohtawa,et al.  Male-specific metabolism of simvastatin by rat liver microsomes. , 1991, Chemical & pharmaceutical bulletin.

[36]  J. Neaton,et al.  Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). , 1986, JAMA.

[37]  M. Kuroda,et al.  Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. , 2004, FEBS letters.

[38]  Y. Tsujita,et al.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.